
News|Articles|May 1, 2002
Warning against enoxaparin's use in patients with prosthetic heart values, new teratogenic effects.
Enoxaparin sodium (Lovenox injection, Aventis) is not recommended for thromboprophylaxis in patients with prosthetic heart values and particularly in pregnant women with prosthetic heart valves, according to revised product labeling.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Schizophrenia, Bipolar Disorder, and MDD Linked to Increased Risk for Developing Long COVID
2
Health Plans Beware: Keep Contract Language Tight If Your PBM Wants Rebate Guarantees Renegotiated Because of the IRA and Biosimilars | AMCP Nexus 2025
3
PBMs Make a Case for the GLP-1 Teeter Totter: Up on the Pharmacy Benefit, Down on the Medical One | AMCP Nexus 2025
4
Lumakras Can Trigger ILD. New Findings Suggest Why
5

















































